Table 4.
False negative rate of each assay
| Assay | Days of symptoms |
|||
|---|---|---|---|---|
| 1–6 (n=80) | 7–13 (n=37) | 14–20 (n=26) | 21–64 (n=30) | |
| Abbott | 7 (8.8)b 3.6–17.2 |
9 (24.3) 11.8–41.2 |
2 (7.7) 0.94–25.1 |
4 (13.3)b 3.8–30.7 |
| Beckmana | 3 (3.9) 0.9–10.6 |
11 (31.4)d 15.9–47.0 |
2 (8.3) 0.94–25.1 |
2 (6.7) 0.82–22.1 |
| Roche | 6 (7.5) 2.8–15.6 |
10 (27.0)e 13.8–44.1 |
1 (3.8) 0.10–19.6 |
2 (6.7) 0.82–22.1 |
| OCD | 1 (1.3)c 0.03–6.8 |
3 (8.1)c 1.7–21.9 |
1 (3.8) 0.10–19.6 |
1 (3.3) 0.08–17.2 |
| Siemens | 5 (6.3) 2.1–14.0 |
12 (32.4)b 18.0–49.8 |
3 (11.5) 2.4–30.1 |
2 (6.7) 0.82–22.1 |
| cPass | 6 (7.5) 2.8–15.6 |
6 (16.2) 6.2–32.0 |
2 (7.7) 0.94–25.1 |
0 (0.0)c 0.0–11.6 |
| Significant differences | ||||
| (b–c) | 7.5% 95% CI 0.8–14.2 p=0.030 |
24.3% 95% CI 6.8–41.8 p=0.009 |
13.3% 95% CI 1.1–25.4 p=0.039 |
|
| (d–c) | 23.3% 95% CI 4.4–38.7 p=0.010 |
|||
| (e–c) | 18.9% 95% CI 2.1–35.7 p=0.033 |
|||
Values are n (%), 95% CI.
a
Day 1–6: 1 equivocal and 3 insufficient omitted; Day 7–13 and Day 14–20: 1 equivocal and 1 insufficient omitted; Day ≥21: 1 equivocal omitted.
b–e
See significant differences section of table.